We’re rated Excellent
4.7 out of 5 based on 100 reviews

Light Autumnal Reading Oct 22

Lilly bets more than $600M on a gene therapy developer targeting hearing loss

Lilly bets more than $600M on a gene therapy developer targeting hearing loss | BioPharma Dive

A stem cell aging framework, from mechanisms to interventions

A stem cell aging framework, from mechanisms to interventions: Cell Reports

Healthy aging and the human gut microbiome: why we cannot just turn back the clock

Healthy aging and the human gut microbiome: why we cannot just turn back the clock | Nature Aging

‘In vivo’ cell therapy: expanding beyond CAR-T

At least five startups have emerged with new ways to genetically modify immune cells within the body, an approach that, if successful, could widen the field of CAR-T treatment.

‘In vivo’ cell therapy: expanding beyond CAR-T | BioPharma Dive

The debate over whether aging is a disease rages on

In its latest catalogue of health conditions, the World Health Organization almost equated old age with disease. Then it backed off.

The debate over whether aging is a disease rages on | MIT Technology Review

First known map of night sky found hidden in Medieval parchment

Fabled star catalogue by ancient Greek astronomer Hipparchus had been feared lost.

First known map of night sky found hidden in Medieval parchment (nature.com)

Black Death may have influenced evolution of genes involved in immune responses, study finds

Black Death may have affected evolution of genes tied to immunity (statnews.com)

The bird is fine, the bird is fine, the bird is fine, it’s dead.

The pursuit of immortality is getting older. So are we.

Should we believe in — or even want — immortality? | MIT Technology Review

Nucleome raises £37.5m to shine light on ‘dark genome’

Nucleome raises £37.5m to shine light on 'dark genome' - (pharmaphorum.com)

Gilead, working to improve cancer cell therapy, partners with California startup

Synthetic biology technology developed by the startup, Refuge Biotechnologies, could help Gilead produce safer and more effective CAR-T treatments.

Gilead, working to improve cancer cell therapy, partners with California startup | BioPharma Dive